Clinical and imaging modality factors impacting radiological interpretation of breast screening in young women with neurofibromatosis type 1

被引：0
作者：
Mathilda Wilding
Jane Fleming
Katrina Moore
Ashley Crook
Ranjani Reddy
Sarah Choi
Timothy E. Schlub
Michael Field
Lavvina Thiyagarajan
Jeff Thompson
Yemima Berman
机构：
[1] Royal North Shore Hospital,NSLHD Familial Cancer Service, Department of Cancer Services
[2] Royal North Shore Hospital,Department of Clinical Genetics
[3] Royal North Shore Hospital,Department of Endocrine Surgery
[4] North Shore Radiology & Nuclear Medicine,Sydney School of Public Health, Faculty of Medicine and Health
[5] University of Sydney,Northern Clinical School, Faculty of Health and Medicine
[6] University of Sydney,undefined
来源：
Familial Cancer | 2023年 / 22卷
关键词：
Breast cancer screening; Neurofibromatosis; MRI; Mammogram; Breast density; BI-RADS lesions;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Young women with Neurofibromatosis type 1 (NF1) have a high risk of developing breast cancer and poorer survival following breast cancer diagnosis. International guidelines recommend commencing breast screening between 30 and 35 years; however, the optimal screening modality is unestablished, and previous reports suggest that breast imaging may be complicated by the presence of intramammary and cutaneous neurofibromas (cNFs). The aim of this study was to explore potential barriers to implementation of breast screening for young women with NF1.
引用
收藏
页码：499 / 511
页数：12
相关论文
共 180 条
[1]  
Evans D(2010)Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service Am J Med Genet Part A 152 327-332
[2]  
Howard E(2005)Prevalence of neurofibromatosis 1 in german children at elementary school enrollment Arch Dermatol 141 71-74
[3]  
Giblin C(2018)Prevalence of neurofibromatosis type 1 in the finnish population Genet Med 20 1082-1086
[4]  
Lammert M(2000)Epidemiology of neurofibromatosis type 1 (NF1) in northern finland J Med Genet 37 632-636
[5]  
Friedman JM(2021)Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation Genet Med 17 548-554
[6]  
Kluwe L(2002)Neurofibromatosis 1: clinical manifestations and diagnostic criteria J Child Neurol 34 1978-1986
[7]  
Mautner VF(2016)Distinctive Cancer Associations in patients with neurofibromatosis type 1 J Clin Oncol 19 1187-1191
[8]  
Kallionpaa RA(2011)Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989 Eur J Hum Genet 49 264-269
[9]  
Uusitalo E(2012)Life expectancy in hereditary cancer predisposing diseases: an observational study J Med Genet 68 1110-1118
[10]  
Leppavirta J(2001)Mortality in neurofibromatosis 1: an analysis using U.S. death certificates Am J Hum Genet 116 211-217
12345678910